Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Epidermal radionuclide therapy with rhenium-188 in non-melanoma skin cancer: a short narrative review.

Frontiers in medicine·2026
Same author

Hybrid [<sup>18</sup>F]FDG PET/MR Imaging Parameters for the Prediction of Tissue Biomarkers in Invasive Ductal Breast Cancer.

Bioengineering (Basel, Switzerland)·2026
Same author

Dynamic Total-Body PET Imaging Unfolds [<sup>11</sup>C]Choline Kinetics and Dosimetry in Primary Hyperparathyroidism.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Omitted staging PSMA PET/CT is associated with advance disease extent at time of PSA persistence: a single center retrospective analysis.

European journal of nuclear medicine and molecular imaging·2026
Same author

PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an "EMBARK-Like" cohort.

Prostate cancer and prostatic diseases·2026

Related Experiment Video

Updated: May 12, 2026

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke
12:01

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke

Published on: June 14, 2018

11C-choline PET/CT and PSA kinetics.

Paolo Castellucci1, Maria Picchio

  • 1Nuclear Medicine Unit, Policlinico S Orsola-Malpighi, University of Bologna, Bologna, Italy. paolo.castellucci@aosp.bo.it

European Journal of Nuclear Medicine and Molecular Imaging
|April 13, 2013
PubMed
Summary

Choline PET/CT shows promise for detecting recurrent prostate cancer after initial treatment. This review focuses on its use in patients with rising prostate-specific antigen levels to identify disease recurrence.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • The utility of positron emission tomography/computed tomography (PET/CT) using radiolabeled choline ( (18)F-choline or (11)C-choline) in prostate cancer management post-primary treatment remains undefined.
  • Current clinical guidelines do not specify the appropriate use of this emerging diagnostic imaging technique.

Purpose of the Study:

  • To review existing literature on choline PET/CT in prostate cancer patients with biochemical relapse.
  • To evaluate the relationship between prostate-specific antigen (PSA) levels, PSA kinetics, and choline PET/CT sensitivity.
  • To identify patient selection criteria for optimizing the benefits of choline PET/CT, particularly in early biochemical recurrence.

Main Methods:

  • Literature review of published studies on choline PET/CT in prostate cancer.

More Related Videos

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
09:25

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Published on: October 24, 2019

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat
15:10

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

Related Experiment Videos

Last Updated: May 12, 2026

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke
12:01

PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke

Published on: June 14, 2018

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
09:25

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Published on: October 24, 2019

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat
15:10

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

  • Analysis of studies correlating PSA levels and kinetics with choline PET/CT findings.
  • Focus on diagnostic performance in detecting local, lymph node, and distant recurrence.

    • Main Results:

    • Choline PET/CT demonstrates potential in restaging prostate cancer for patients experiencing biochemical relapse.
    • Sensitivity of choline PET/CT appears linked to PSA levels and their rate of increase.
    • The modality aids in detecting local, lymph node, and distant metastatic recurrence.

    Conclusions:

    • Choline PET/CT is a valuable tool for detecting prostate cancer recurrence, especially in cases of biochemical relapse.
    • Optimizing patient selection based on PSA dynamics can enhance the diagnostic yield of choline PET/CT.
    • Further guidelines are needed to establish the definitive role of choline PET/CT in post-treatment prostate cancer surveillance.